10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study will use 10x’s Flex Apex and Xenium platforms, with plans to expand to Atera, on tumor samples from patients with advanced cancers evaluated by a clinical molecular tumor board.

The collaboration aims to identify clinically relevant biomarkers that may help predict treatment response and cancer prognosis across multiple solid tumors, including non-small cell lung, breast, bladder cancer and melanoma, and to explore how 10x technologies could complement current standard-of-care clinical assays.

News Market Reaction – TXG

-1.55%

54 alerts

-1.55% Session close to close

+3.3% Peak in 5 hr 50 min

$6.43B Market Cap

0.6x Rel. Volume

In the Jul 29 session, TXG declined 1.55%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 54 alerts that day, indicating high trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

A prior TXG collaboration, historical news_id 1071896, recorded a 1.2% 24-hour reaction. That preced...

Analysis

A prior TXG collaboration, historical news_id 1071896, recorded a 1.2% 24-hour reaction. That precedent frames this announcement as another research expansion, while moderate short positioning and Net Selling insider activity remain relevant risks.

Key Figures

Announcement Date: July 29, 2026 Collaboration Duration: Multi-year Expected Study Size: Hundreds of patients

3 metrics

Announcement Date July 29, 2026 Research collaboration announcement

Collaboration Duration Multi-year Research collaboration with Lausanne University Hospital

Expected Study Size Hundreds of patients Advanced cancer across multiple solid tumor types

Historical Context

5 past events · Latest: Jul 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	earnings scheduling	Neutral	-2.8%	Announced second-quarter 2026 results date and conference call logistics
Jun 17	research collaboration	Positive	+1.2%	Partnered with Cleveland Clinic on bladder-cancer diagnostic research
Jun 09	acquisition announcement	Positive	+4.8%	Acquired Proteintech Genomics to expand single-cell proteomics capabilities
May 07	earnings report	Negative	-3.7%	Reported revenue decline, operating loss, and reaffirmed full-year revenue guidance
Apr 29	conference participation	Neutral	+9.2%	Scheduled management participation in the BofA healthcare conference

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The record showed three aligned and two divergent reactions, with no consistent direction across event types.

Key Terms

single cell, spatial biology, antibody-drug conjugates, bispecific antibodies, +1 more

5 terms

single cell technical

"diagnostic applications of single cell and spatial technologies for cancer care"

Single cell refers to the study or use of an individual cell rather than averaging measurements across many cells. Like listening to a single voice in a crowded room, single-cell approaches reveal differences and rare cell types that bulk measurements hide. For investors, single-cell data can de-risk drug development and diagnostics by pinpointing precise targets, explaining why a therapy works or fails, and enabling more tailored products that may command premium pricing or faster regulatory paths.

spatial biology technical

"complementary expertise in spatial biology, pathology, computational AI"

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

antibody-drug conjugates medical

"therapeutic approaches, including antibody-drug conjugates, bispecific antibodies"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

bispecific antibodies medical

"including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors"

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

immune checkpoint inhibitors medical

"bispecific antibodies and immune checkpoint inhibitors"

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms

PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.

This collaboration builds on 10x's broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies.

Through this multi-year collaboration, the study intends to use 10x's Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumor samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development.

The rapid expansion of targeted therapies, immunotherapies and other emerging treatment modalities is creating new opportunities for treating patients, while also increasing the complexity of treatment decision-making in oncology. As a result, there is a growing need for biomarkers that can help predict which patients are most likely to benefit from specific therapies, supporting more personalized treatment strategies.

"This collaboration brings together complementary expertise in spatial biology, pathology, computational AI and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment," said Raphael Gottardo, Professor and Director of the Biomedical Data Science Center, CHUV. "Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care."

The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.

"The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care."

The collaboration is expected to generate a comprehensive, multimodal resource integrating single cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. It also plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and molecular tumor board decision-making.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

About Lausanne University Hospital (CHUV)

Lausanne University Hospital (CHUV) is one of Switzerland's leading academic medical centers, uniting clinical excellence, biomedical research, and medical education under one roof. Consistently ranked among the world's best hospitals by Newsweek, CHUV also serves as a think tank driving forward research and medicine – bringing together clinicians, pathologists, computational scientists, and translational researchers to accelerate the development of precision medicine. Through multidisciplinary programs spanning cancer research, advanced imaging, digital pathology, artificial intelligence, and spatial biology, CHUV is pioneering next-generation biomarkers and diagnostics – improving patient outcomes and enabling more personalized treatment decisions. To learn more, visit https://www.chuv.ch or connect with us on LinkedIn, Facebook, Instagram, YouTube.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-and-lausanne-university-hospital-collaborate-to-advance-research-in-diagnostic-applications-of-single-cell-and-spatial-technologies-for-cancer-care-302837205.html

SOURCE 10x Genomics, Inc.

FAQ

What is the new collaboration between 10x Genomics (TXG) and Lausanne University Hospital announced in July 2026?

The collaboration is a multi-year research partnership to study diagnostic applications of single cell and spatial technologies in cancer care. According to 10x Genomics, it focuses on advanced cancer patients evaluated by a clinical molecular tumor board, aiming to uncover clinically relevant biomarkers for treatment guidance.

Which cancers are included in the 10x Genomics (TXG) and CHUV biomarker study?

The study is expected to include patients with several solid tumor types, notably non-small cell lung cancer, breast cancer, bladder cancer and melanoma. According to 10x Genomics, it will enroll hundreds of patients to analyze treatment response and resistance across diverse therapeutic approaches in oncology.

Which 10x Genomics technologies are used in the CHUV cancer diagnostics collaboration?

The collaboration plans to use 10x Genomics’ Flex Apex and Xenium platforms, with a goal to expand to the Atera platform. According to 10x Genomics, these single cell and spatial tools will generate multimodal tumor data to support biomarker discovery and potential future diagnostic applications in cancer care.

How could the 10x Genomics (TXG) and CHUV study impact precision oncology diagnostics?

The study intends to identify clinically actionable biomarkers that may predict treatment response and prognosis in cancer. According to 10x Genomics, resulting biomarker insights could inform future diagnostic frameworks and support personalized treatment planning and molecular tumor board decision-making in routine oncology practice.

How many patients will be involved in the 10x Genomics and Lausanne University Hospital cancer biomarker research?

The research is expected to include hundreds of patients with advanced cancers across multiple solid tumor types. According to 10x Genomics, integrating these patients’ single cell, spatial and clinical outcomes data may create a comprehensive resource on mechanisms of response and resistance to modern therapies.